Olanexidine is a monobiguanide compound with bactericidal activity.

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM, reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 uM in A549 cells.

OGT inhibitor 4a (OSMI-4 active form) is a novel potent, selective O-linked N-acetylglucosamine transferase (OGT) inhibitor with Kd of 8 nM, the active form of OSMI-4..

Officinalisinin I is a steroidal saponin, isolated from Anemarrhena asphodeloides.

ODQ (sGC inhibitor ODQ) is a potent, selective, irreversible inhibitor of sGC (soluble guanylyl cyclase).

Odalasvir (ACH-3102, JNJ-64289901) is a potent, second-generation HCV NS5A inhibitor in development for the treatment of hepatitis C..

Octopamine (OA), a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates.

Octahydrocurcumin is a hydrogenated derivatives of curcumin; metabolite of curcumin.

Ochratoxin B(OTB) is a non-chlorinated analog of OTA that has cytotoxic effects on kidney and liver cells in vitro but only minor effects in vivo, due to its rapid metabolism and excretion.

Ochratoxin A demonstrates nephrotoxicity and teratogenesis in animals, and shows inhibition of bacterial, yeast, and liver FARSL (phenylalanyl-tRNA synthetases) competitive with phenylalanine.

OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.

OBA-09 is a simple ester of pyruvate and salicylic acid, main metabolites of pyruvate and aspirin, respectively, exerts robust neuroprotective effect in the postischemic brain in vivo.

OADS is a specific, reversible, small-molecule inhibitor directs against CLC (Chloride Channel) antiporter with Ki of 29 uM, has no specific effect on a CLC channel (ClC-1). .

O-1602 (O1602) is an atypical cannabinoid, potent and selective agonist of GPR55 cannabinoid receptor with EC50 of 13 nM, shows no significant activity for CB1 and CB2 receptors (EC50>30 uM).

NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1..

NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively.

NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays.

NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively.

NXL101 is a novel quinoline bacterial DNA gyrase and topoisomerase IV inhibitor that shows potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains.

NVS-CRF38 is a potent, selective, orally bioavailable corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50 of 70 nM..

NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM.

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

NV03 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain with Kd of 2.4 uM..

NV01 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain (TTD) with Kd of 5 uM..

Nuclear yellow (Hoechst S769121) exhibits excitation/emission maxima ~335/495 nm when bound to DNA.

NTRC-844 (NTRC844) is a potent, selective neurotensin receptor type 2 (NTS2) with Ki of 23 nM, 100-fold selectivity over NTS1 receptor.

NSC668394 (NSC 668394) is a small molecule inhibitor of ezrin, directly bind to ezrin with Kd of 12.59 uM.

NSC49652 (NSC 49652) is a compound targeting the transmembrane domain (TMD) of death receptor p75NTR with IC50 of 10 uM in AraTM assays, alters the relative conformation of p75NTR TMDs and induces dynamic changes in the full-length receptor in mammalian c